Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy.

NCT05789797 is registered in ClinicalTrials.gov with POLYSAN Scientific & Technological Pharmaceutical Company as lead sponsor.

NCT NCT05789797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05789797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy.
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Phase
Observational
Overall status
Completed
Start date
May 12, 2022
Completion date
December 16, 2024
Enrollment
368 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, drug induced liver injury